Parkinson ’ s disease. Function Anatomy of Parkinson ’ s Disease.

Slides:



Advertisements
Similar presentations
Pharmacological Management of Parkinson’s Disease
Advertisements

Parkinson Disease (PD) Treatment Update. Outlines The Basics: – PD Introduction and motor symptoms. – DDx not to miss. – Different classes of Anti PD.
Parkinson’s disease Dartington 26 June 2003
Drugs That Act On The Central Nervous System SAMUEL AGUAZIM( MD)
Extrapyramidal diseases. Ⅰ.Formation of basal ganglia *Corpus striatum:/caudate nucleus \ neostriatum \lentiform/putamen nucleus / \lentiform/putamen.
Diagnosis and Management of Parkinson’s Disease
Parkinson’s Disease (PD)
Parkinson’s Disease Dr Rachel Cary, Warwick Hospital.
Diagnosis and Treatment of Parkinson’s Disease Jeff Bronstein, MD, PhD Professor of Neurology at UCLA Director of the SW PADRECC Director of UCLA Movement.
Neurology and Rehabilitation Target Day Parkinson’s Disease Dr Bruce Covell Amanda Horlor Linda Lloyd.
Parkinson’s Disease: A Brief Overview
Drugs Used to Treat Parkinson’s Disease By Jasmine and Morgan 11/13/03.
Paul Short, Ph.D. The Parkinson’s Coach NEUROPSYCHOLOGY OF PARKINSON’S COMMUNICATION PROBLEMS.
Initial Diagnosis and Management of Parkinson’s Disease
Harald Bjorndalen Adapted from lecture by Dr Zoe Campbell (Medical SpR)
Parkinson’s Disease By Nik Sanyal.
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Erica Partridge Parkinson’s Disease. Definition Aetiology PD vs Parkinsonism Symptoms and signs Differentials Investigations Management Prognosis.
PARKINSON’S DISEASE Diagnosis & Treatment Options University of South Carolina School of Medicine March 27, 2014 Dale R.Hamrick, MD PO Box Columbia,
Cathy Chuang, MD Jacobi Medical Center Department of Neurology
JP Parkinson’s Disease. Overview Idiopathic PD Clinically and pathologically distinct from other parkinsonian syndromes Degenerative disorder of the CNS.
Parkinson’s Disease By Devin Cornford
Parkinson ’ s A Review and Practical Guide to a Common and Complex Disease.
Chapter 30 Agents Used to Treat Parkinson’s Disease.
Duodenal Levodopa Treatment in advanced Parkinson’s Disease
Drugs for Parkinon’s disease Parkinson's disease –progressive tremor –Bradykinesia and rigidity –degeneration of the dopaminergic nigrostriatal pathway.
Drugs of Anti-Parkinson’s disease Department of Pharmacology Zhang Yan-mei.
Parkinson’s Plus By: Glen Estrosos.
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
Movement Disorders Mary Quiceno, M.D. Neurology. Hypokinetic & Hyperkinetic Movement Disorders  Parkinson’s disease  Parkinson’s Plus Syndromes –PSP.
Parkinson’s Disease superKAT :).
Alzheimer’s Disease The most common cause of Dementia –Progressive Memory Loss Plus loss in one other area of cognition: Perception Attention Language/Symbols.
By Prof. Hanan Hagar Pharmacology unit Medical College.
Surgery for Parkinson’s Disease: Focus on Deep Brain Stimulation Ramón L Rodríguez, MD Director of Clinical Services University of Florida Movement Disorders.
Treatment of Parkinson Disease David Tran, 2013 Mercer University PharmD Candidate.
Movement Disorders K. Zárubová. Movement disorders MD - abnornal involuntary movements dysfunction of basal ganglia (anatomically) dysfunction of extrapyramidal.
Treatment of Parkinson’s Disease Christopher Buchanan CHEM 5398/Buynak April 3, 2007.
Mostly Parkinson’s disease but also few other movement disorders due to diseases of the basal ganglia.
Benjamin L. Walter M.D. Medical Director, Deep Brain Stimulation Program Neurological Institute University Hospitals Case Medical Center Management of.
Represented by SHIVAJI SINGH SAMEER CHAVAN SOURIMA MUKHERJEE SONAL KULKARNI SUVARNA CHAVAN M.Sc (CLINICAL RESEARCH) (CRANFIELD)GROUP-9.
Group 5.  100+  Precise roles not known  3 categories.
Drugs used in parkinsonism
By Prof. Hanan Hagar Pharmacology unit Medical College.
A neurology primer. Idiopathic Parkinson Disease (also referred to as primary or classical Parkinson disease)  is a progressive neurodegenerative disorder.
By Prof. Hanan Hagar Pharmacology unit Medical College.
Parkinson's Disease ILOs
Parkinson's disease By Colby Allen. symptoms Mild to major tremors. Rigidity or joint stiffness Bradykinesia or slowness of movement Postural instability.
Drugs in parkinsonism ilos
Parkinson’s Disease Angela Duncan June Why I Chose This Subject Common neurodegenerative disorder / in Scotland Expected increase.
Pathogenesis and pathology of parkinsonism
ANTI- PARKINSONISM Dr: Samah Gaafar Al-shaygi.  Neurodegenerative diseases.  Dopamenergic neurones in substantia nigra.  Environmental* genetic factors.
ANTI-PARKINSONIAN DRUGS. Parkinsonism It is a common movement disorder that involves dysfunction in the basal ganglia and associated brain structures.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Pharmacological Treatment of Parkinson Disease: A.
Parkinson’s Disease superKAT :).
Parkinson’s disease by Syed Baseeruddin Alvi (09).
A Primer for Clinicians and Administrators
Parkinson's disease.
Drugs Used for Parkinson’s Disease
Parkinson’s Disease.
Parkinsonism.
MOVEMENT DISORDERS.
Drugs of Anti-Parkinson’s disease
Lecture 3 Dr.Narmin Hussen
Drugs for Parkinson’s Disease
ANTIPARKINSONS Drugs By Dr. Mirza Shahed Baig.
מחלת פרקינסון מחלת פרקינסון היא מחלה Progressive.
Anti-parkinsonism Drugs
Pharmacological Management of Parkinson’s Disease
Neurodegenerative diseases
Parkinson’s Disease Definitions Disease features Pathology
Presentation transcript:

Parkinson ’ s disease

Function Anatomy of Parkinson ’ s Disease

Parkinson ’ s disease (PD),which is also called paralysis agitans , is a common degenerative disease of the nervous system in middle and old-age. PD is a clinical disease dominated by four important signs:  tremor at rest  bradykinesia  rigidity  postural instability and gait difficulty

Etiology

Primary (Idiopathic) PD  Age  Environment  MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine)  Heredity  P4502D2 gene  а-synuclein gene  Parkin gene

Secondary (Acquired, symptomatic) PD  Post-encephalitic Pakinsonism  Drugs-induced or toxins-induced Pakinsonism  Vascular Pakinsonism

Pathology

Pathophysiology

The metabolism of levodopa The metabolism of levodopa 左 旋 多 巴 Levodopa 左 旋 多 巴 Levodopa 3 - 氧- 甲 基 多 巴 ( 3- OMD) 多 巴 胺 Dopamine 左 旋 多 巴 Levodopa 3 - 氧- 甲 基 多 巴 ( 3- OMD) 3 - 氧- 甲 基 多 巴 ( 3- OMD) 甲 氧 基- 络 胺 (3-MT) 甲 氧 基- 络 胺 (3-MT) 二 羧 基- 苯- 乙 酸 (DOPAC) 二 羧 基- 苯- 乙 酸 (DOPAC) 高 香 草 酸 (HVA) 高 香 草 酸 (HVA) 多 巴 胺 (Dopamine) 多 巴 胺 (Dopamine) COMT X X COMT COMT MAO MAO X X X 多 巴 脱 羧 酶 DDC 多 巴 脱 羧 酶 DDC Tolcapone Tolcapone 外 周 外 周 脑 内 脑 内 载 体 载 体 苄 丝 肼卡 比 多 巴 苄 丝 肼卡 比 多 巴

Clinical manifestations

 1. tremor  2 rigidity  lead-pipe phenomenon  cogwheel phenomenon  head dropping test  road market phenomenon  3, bradykinesia  4 postural instability and gait difficulty :  Festination gait

Clinical manifestations Some patient may have the other non- motor manifestations of PD such as autonomic dysfunction, personality changes,dementia, depression and visual hallucination, but usually don ’ t serious.

Laboratory examination  1.The HVA dose in cerebrospinal fluid and urine.  2. Southern blot 、 PCR 、 DNA analysis  3. PET 、 SPECT

Diagnosis It ’ s usually not difficulty to diagnose PD according to the age at onset, symptoms and course of the disease. The coherence of PD clinical diagnosis is 85% with the pathology.

Differential diagnosis  1.Secondary Pakinsonism  2.Major depression (MD)  3.Essential tremor (ET)  4.Other nervous system degeneration disease with the PD sympotom  5.Diffuse Lewey body disease (DLBD)  6.Hepatolenticular degeneration (HLD)  7.Huntington ’ s disease (HD)

Differential diagnosis  8.Multiple system atrophy (MSA):  ① Striatonigral degeneration (SND)  ② Shy-Drager syndrome (SDS)  ③ Olivoponcerebellar atrophy (OPCA)  9.Progressive supraneuclear palsy (PSP)  10.Corticalbasal degeneration (CBGD)

Treatment

1.Drug  (1)Anticholinergic drugs:  Adam: 1~2mg tid P.O.  (2) Amantadine

1.Drug  (3) Levodopa and Compound levodopa :  ① L-Dopa  ② Compound L-Dopa :  madopar  Sinemet  madopar dispersible  Sinemet CR

L-Dopa and the complication Effect complication Course of the disease 5 years wearing-off on-off phenomenon Dyskimsia Gait freezing DA deposit Cognitive disorder 1.47

Side-effects of L-Dopa  Peripheral : nausea, vomit, hypotension, arrhythmia  Central :  Motor fluctuation:  (1) wearing-off  (2) on-off phenomenon  Dyskimsia :  (1) peak-dose dyskimsia  (2) biphasic dyskinesia  (3) dystonia  Psychiatric sympotoms

1.Drug  Dopamine agonists, DAs :  Bromocriptin  Pergolide  Lisuride  Trastal SR  Apomorphine  Bromocriptin : have large agonism to D2 receptor but small antagonism to D1 receptor  Pergolide : have agonism to both D1 and D2 receptor

1.Drug  (5)Monoamine oxidase type B ( MAO-B ) :  Deprenyl  (6)Catechol O-methyltransferase (COMT) inhibitors:  Tacapone  Entacopone

Other treatments  2.Surgery The most common methods :  Stereotaxic thalamotomy  Pallidotomy  Deep brain stimulation (DBS)  3.Transplantation of fetal dopamine neurons or gene therapy.  4.Neurologic rehabilitation.